BioNTech Faces Twin Catalysts: FDA Vaccine Vote and ASCO Cancer Readouts

BioNTech's defining week includes FDA vote on next Covid vaccine and ASCO release of promising Pumitamig data, as the company restructures for post-pandemic reality.

BioNTech enters a defining week where two major events collide — a Food and Drug Administration advisory committee vote on the next Covid vaccine formulation and the release of fresh oncology data at the American Society of Clinical Oncology meeting. The outcome of either could reshape the narrative around a stock that has been drifting since the pandemic boom faded.

On Thursday, May 28, the FDA’s Vaccines and Related Biological Products Advisory Committee will weigh in on the recommended composition for the 2026/27 respiratory season. At the heart of the discussion is the XFG subvariant, now the dominant virus lineage in the United States. BioNTech has signalled it can pivot to an XFG-adapted mRNA shot quickly if the committee gives the nod. The vote comes amid an unsettled regulatory backdrop: FDA Commissioner Marty Makary stepped down recently, leaving the vaccine division under interim leadership.

The following day, ASCO’s annual meeting kicks off in Chicago from May 29 through June 2, where BioNTech plans to unveil a slate of cancer data. The spotlight falls on Pumitamig, a bispecific antibody developed with Bristol Myers Squibb that targets both PD-L1 and VEGF-A. In the ROSETTA-Lung-02 study, Pumitamig delivered an overall response rate of 70 percent and a disease control rate of 100 percent in the evaluable cohort — figures that edge past the 67.6 percent response and 12.4-month median progression-free survival posted by Pfizer and 3SBio’s competing candidate, PF-08634404. The durability and safety profile will be scrutinized when the full dataset is presented.

Beyond Pumitamig, BioNTech will showcase data on Gotistobart, a selective Treg modulator, and Trastuzumab Pamirtecan, an antibody-drug conjugate for recurrent endometrial cancer. The company now has more than 25 Phase 2 and Phase 3 studies running across its oncology pipeline. A rival bispecific, Akeso and Summit’s Ivonescimab, already has a PDUFA date of November 14, 2026, and Phase 3 overall survival results from the HARMONi-6 trial are due around the same time, setting up a direct comparison in lung cancer.

The push into oncology comes as BioNTech restructures its operations to reflect a post-pandemic reality. First-quarter revenue fell to €118.1 million from €182.8 million a year earlier, and the net loss widened to €531.9 million as demand for Covid vaccines normalised. To cut costs, the company will close manufacturing sites in Singapore and several facilities in Germany by the end of 2027, affecting roughly 1,860 jobs. The measures are expected to generate annual savings of around €500 million from 2029. Co-founders U?ur ?ahin and Özlem Türeci plan to hand over their operational leadership roles by the end of 2026 to focus on a new research initiative.

Despite the losses, BioNTech’s balance sheet remains robust. Cash and securities stood at roughly €16.8 billion at the end of March. Shareholders have authorised a buyback programme of up to $1 billion over the next twelve months. Management kept its full-year 2026 revenue guidance unchanged at €2.0 billion to €2.3 billion.

The stock has been cautious ahead of the twin events. Shares traded at €79.70 on Tuesday, down 0.13 percent on the day but up 5.28 percent over the past week. On a monthly basis, however, the decline stands at 10.15 percent. The equity sits 1.63 percent below its 50-day moving average and 7.67 percent below the 200-day line. The broader biotech backdrop has been supportive — the Nasdaq rose 1.01 percent recently and the Russell 2000 climbed 1.48 percent, with sentiment in oncology names lifted by strong data from Akari Therapeutics on pancreatic cancer.

The next few days will determine whether these catalysts can push BioNTech’s stock back toward its 52-week high of roughly €102, from which it is still down about 22 percent. A favourable FDA vaccine vote and convincing ASCO data would give the company two separate growth narratives to rebuild investor confidence. A miss on either front could prolong the current recovery slog. The BIO International Convention, running from June 22 to 25 in San Diego, will offer another chance to reinforce the oncology story if this week’s readouts hold up.